Abbott Laboratories

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$206Mgeneral payments (2019-2025)
$1.6Mresearch payments (2019-2025)
184,301clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $28M
2020 $18M
2021 $23M
2022 $31M
2023 $35M
2024 $34M
2025 $36M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Clinical Cardiac Electrophysiology $36M
Cardiovascular Disease $30M
Interventional Cardiology $29M
Neurological Surgery $9.5M
Thoracic Surgery (Cardiothoracic Vascular Surgery) $9.3M
Interventional Pain Medicine $8.3M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Claudio Feler Cheyenne, WY Neurological Surgery $5,288,692.64
Robert Alpern New Haven, CT Nephrology (Internal Medicine) $2,803,423.53
Steven Falowski Fountain Hill, PA Neurological Surgery $1,641,570.89
Mikhail Varshavski Chatham, NJ Family Medicine $1,422,598.64
Michael Delaughter Bedford, TX Clinical Cardiac Electrophysiology $1,394,434.55
Timothy Deer Charleston, WV Interventional Pain Medicine $1,211,179.82
Leslie Saxon Los Angeles, CA Clinical Cardiac Electrophysiology $1,065,632.73
Bradley Vilims Lakewood, CO Interventional Pain Medicine $977,131.22
Pankaj Mehta Killeen, TX Interventional Pain Medicine $967,995.48
Robert Percell Lincoln, NE Cardiovascular Disease $812,648.53

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.